Making protein interactions druggable: targeting PDZ domains

Nat Rev Drug Discov. 2004 Dec;3(12):1047-56. doi: 10.1038/nrd1578.

Abstract

Modulating protein-protein interactions involved in disease pathways is an attractive strategy for developing drugs, but remains a challenge to achieve. One approach is to target certain domains within proteins that mediate these interactions. One example of such a domain is the PDZ domain, which is involved in interactions between many different proteins in a variety of cellular contexts. Because PDZ domains have well-defined binding sites, they are promising targets for drug discovery. However, there is still much to learn about the function of these domains before drugs targeting PDZ interactions can become a reality.

Publication types

  • Review

MeSH terms

  • Animals
  • Carrier Proteins / antagonists & inhibitors
  • Carrier Proteins / metabolism
  • Drug Delivery Systems / methods*
  • Humans
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / metabolism*
  • Nerve Tissue Proteins / antagonists & inhibitors
  • Nerve Tissue Proteins / metabolism*
  • Nuclear Proteins / antagonists & inhibitors
  • Nuclear Proteins / metabolism
  • Phosphoproteins / antagonists & inhibitors
  • Phosphoproteins / metabolism*
  • Protein Binding / drug effects
  • Protein Structure, Tertiary / drug effects
  • Proteins / antagonists & inhibitors
  • Proteins / metabolism*
  • SAP90-PSD95 Associated Proteins
  • Zonula Occludens-1 Protein

Substances

  • Carrier Proteins
  • Membrane Proteins
  • Nerve Tissue Proteins
  • Nuclear Proteins
  • PICk1 protein, human
  • Phosphoproteins
  • Proteins
  • SAP90-PSD95 Associated Proteins
  • TJP1 protein, human
  • Zonula Occludens-1 Protein
  • postsynaptic density proteins